We combine deep proteomics with machine learning to better combat complex diseases and create a healthier world.
.png)
.png)
.png)
To open the bottlenecks of discovery, we rely on the talent intersection of cutting-edge biology, proteomics, powerful software, and machine learning capabilities. This has been our compass for building our company from day one.
%20(1).png)
.png)
Prof. Giulio Draetta, M.D., Ph.D., is senior vice president and chief scientific officer at The University of Texas MD Anderson Cancer Center. Prof. Draetta is also a member of MD Anderson’s faculty as a professor of Genomic Medicine and the Sewell Family Distinguished University Chair. As chief scientific officer, he provides focused leadership for the institution’s diverse scientific and clinical research faculty, championing innovation and team science, and fostering strong partnerships with the cancer research community worldwide.
Prof. Giulio Draetta, M.D., Ph.D., is senior vice president and chief scientific officer at The University of Texas MD Anderson Cancer Center. Prof. Draetta is also a member of MD Anderson’s faculty as a professor of Genomic Medicine and the Sewell Family Distinguished University Chair. As chief scientific officer, he provides focused leadership for the institution’s diverse scientific and clinical research faculty, championing innovation and team science, and fostering strong partnerships with the cancer research community worldwide.
Prof Tami Geiger from the Weizmann Institute of Science, is a world leader in clinical cancer proteomics. Her lab uses state of the art mass spectrometry-based proteomics technology to study cancer progression and drug resistance mechanisms. Her research combines proteomic method development with basic biological research and bioinformatics. Ultimately, her research aims toward cancer biomarker discovery, and provides better understanding of cancer transformation processes.
Prof Tami Geiger from the Weizmann Institute of Science, is a world leader in clinical cancer proteomics. Her lab uses state of the art mass spectrometry-based proteomics technology to study cancer progression and drug resistance mechanisms. Her research combines proteomic method development with basic biological research and bioinformatics. Ultimately, her research aims toward cancer biomarker discovery, and provides better understanding of cancer transformation processes.
Dr. Shacham is a serial entrepreneur in the fields of Biotech and climate. Dr. Shacham is currently a co-founder and general partner at E44 Ventures, a new studio venture focused on partnering with academia and early ideators, to build technology-based companies to contribute to a cleaner, more sustainable future for our planet. Prior to that, Dr. Shacham founded Karyopharm Therapeutics (NASDAQ: KPTI) where she created the novel oral cancer drug Xpovio® , and led its development from idea to commercialization: Xpovio is now approved worldwide.
Dr. Shacham is a serial entrepreneur in the fields of Biotech and climate. Dr. Shacham is currently a co-founder and general partner at E44 Ventures, a new studio venture focused on partnering with academia and early ideators, to build technology-based companies to contribute to a cleaner, more sustainable future for our planet. Prior to that, Dr. Shacham founded Karyopharm Therapeutics (NASDAQ: KPTI) where she created the novel oral cancer drug Xpovio® , and led its development from idea to commercialization: Xpovio is now approved worldwide.
Prof. Funda Meric-Bernstam has made internationally recognized contributions to precision oncology. As leader of one of the largest Phase I programs in the world, she has focused drug development on identifying single agents and combinations of drugs that target subsets of cancers from multiple sites with innovative basket trials.
Prof. Funda Meric-Bernstam has made internationally recognized contributions to precision oncology. As leader of one of the largest Phase I programs in the world, she has focused drug development on identifying single agents and combinations of drugs that target subsets of cancers from multiple sites with innovative basket trials.
Alexey Nesvizhskii is endowed Godfrey Dorr Stobbe Professor of Bioinformatics in the Departments of Pathology and Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor. His research laboratory is working in the areas of mass spectrometry-based proteomics and proteogenomics, bioinformatics, and multi-omics data integration. The computational methods and tools developed by Dr. Nesvizhskii and his colleagues are used by thousands of laboratories worldwide
Alexey Nesvizhskii is endowed Godfrey Dorr Stobbe Professor of Bioinformatics in the Departments of Pathology and Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor. His research laboratory is working in the areas of mass spectrometry-based proteomics and proteogenomics, bioinformatics, and multi-omics data integration. The computational methods and tools developed by Dr. Nesvizhskii and his colleagues are used by thousands of laboratories worldwide
Dr. Moll is a serial drug hunter focused on cancer research and preclinical development with over twenty years experience in leadership positions in big pharma such as Pharmacia, Pfizer, Boehringer-Ingelheim, and Sanofi. His expertise lies in both cancer cell targeted and IO assets, using different modalities such as small molecules, antibodies and nanobodies. He has a proven track record of initiating and progressing targets and drugs in Oncology.
Dr. Moll is a serial drug hunter focused on cancer research and preclinical development with over twenty years experience in leadership positions in big pharma such as Pharmacia, Pfizer, Boehringer-Ingelheim, and Sanofi. His expertise lies in both cancer cell targeted and IO assets, using different modalities such as small molecules, antibodies and nanobodies. He has a proven track record of initiating and progressing targets and drugs in Oncology.
Dr. Annalisa D’Andrea is a seasoned biotechnology executive with over 25 years of experience in drug discovery and development, particularly in immunology and inflammation. She currently serves as the Chief Scientific Officer (CSO) at Immunitas Therapeutics, a clinical-stage precision immunotherapy company focused on developing novel treatments for cancer.
Dr. Annalisa D’Andrea is a seasoned biotechnology executive with over 25 years of experience in drug discovery and development, particularly in immunology and inflammation. She currently serves as the Chief Scientific Officer (CSO) at Immunitas Therapeutics, a clinical-stage precision immunotherapy company focused on developing novel treatments for cancer.
Dr. Jones brings decades of experience in pharmaceutical R&D and leadership roles. He has been instrumental in progressing multiple therapeutic programs from discovery into clinical development, and will advise Protai on strategic target selection and development paths.
Dr. Jones brings decades of experience in pharmaceutical R&D and leadership roles. He has been instrumental in progressing multiple therapeutic programs from discovery into clinical development, and will advise Protai on strategic target selection and development paths.
A pioneer in the field of targeted protein degradation, Dr. Churcher has led discovery teams at leading biopharma organizations, shaping the early development of PROTAC and induced-proximity modalities. His expertise will help Protai design and optimize degrader molecules with improved selectivity and efficacy.
A pioneer in the field of targeted protein degradation, Dr. Churcher has led discovery teams at leading biopharma organizations, shaping the early development of PROTAC and induced-proximity modalities. His expertise will help Protai design and optimize degrader molecules with improved selectivity and efficacy.
Get in touch with us for questions and potential collaborations.
